An analysis of symptom burden and its predictive factors in patients with prostate cancer
Xiaodan Zhu, Zhenqi Lu, Xiaofeng Gu
Published 2019-05-21
Cite as Chin J Prac Nurs, 2019, 35(15): 1168-1172. DOI: 10.3760/cma.j.issn.1672-7088.2019.15.011
Abstract
ObjectiveTo assess the symptom burden and its predictive factors in patients with prostate cancer.
MethodsA cross-sectional study of 370 men with prostate cancer were conducted in the department of urology, Fudan University Shanghai Cancer Center. The questionnaire included a general questionnaire, Expanded Prostate Cancer Index Composite 26-item version (EPIC-26) and Hospital Anxiety and Depression Scale (HADS).
ResultsThe average score of EPIC-26 in patients with prostate cancer was 25.32±12.00. The sexual function (15.59±7.38) and endocrine disorder (4.09±3.70) scored higher in five domains. There were significant differences in symptom burden scores among different treatment methods (P < 0.01). Multiple linear regression showed that endocrine therapy, anxiety, prostate specific antigen (PSA) and income were the influencing factors of symptom burden in this population, which could explain 49.3% of symptom burden.
ConclusionsThe symptom burden of patients with prostate cancer is heavy, especially during endocrine therapy. Health care provider should focus on assessing the psychology of them. What′s more, it is important to develop the symptom management and psychological support, especially for patients with lower income and advanced patients.
Key words:
Prostate neoplasm; Symptom burden; Predictive factors
Contributor Information
Xiaodan Zhu
Nursing Department of Tumor Hospital Affiliated to Fudan University, Shanghai 200032, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
Zhenqi Lu
Nursing Department of Tumor Hospital Affiliated to Fudan University, Shanghai 200032, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
Xiaofeng Gu
Nursing Department of Tumor Hospital Affiliated to Fudan University, Shanghai 200032, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
